dr. mesa on challenges in myelofibrosis treatment
Published 4 years ago • 134 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
0:58
dr. mesa on challenges with jak inhibitors in myelofibrosis
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment
-
1:33
dr. mesa on late-stage trials in myelofibrosis
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
0:59
dr. michaelis on fedratinib in myelofibrosis treatment
-
1:52
dr. mesa on investigative therapies in myelofibrosis
-
1:32
dr. mesa on emerging therapies in myelofibrosis
-
1:30
dr. michaelis on unanswered questions in myelofibrosis treatment
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
1:08
dr. mesa on unanswered questions regarding jak inhibitors in myelofibrosis
-
1:13
dr. mesa on new trials and agents in the pipeline in myelofibrosis
-
1:29
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
2:13
dr. mesa on the efficacy of fedratinib in patients with myelofibrosis and low platelet counts
-
1:48
dr. mesa on pacritinib for myelofibrosis
-
1:14
dr. mesa on the emergence of jak inhibitors in myelofibrosis
-
1:12
dr. mesa on the differences between fedratinib and ruxolitinib in myelofibrosis
-
1:16
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
1:14
dr. mesa on the safety profiles of jak inhibitors in myelofibrosis
-
1:42
dr. mesa on jak inhibitors in the pipeline for myelofibrosis